Strategy

OKRs, roadmap, and enterprise risk register · reviewed every two weeks by leadership and quarterly with board.

Objective

Become category leader in AI radiology

Reach $100M ARR by EOY FY2678%

Expand to 600 hospitals globally69%

10 FDA-cleared models in production80%

Objective

Deliver world-class clinical outcomes

Median TAT ≤ 10 min across fleet88%

Publish 8 peer-reviewed outcome studies62%

NPS ≥ 70 from chief radiologists92%

Objective

Operate with elite engineering & trust

Platform uptime ≥ 99.99%99%

SOC 2 Type II + HITRUST r275%

Reduce inference cost / study by 40%58%

Roadmap

Q2 FY26 · now

BrainSeg-MR v3.1 (recalibrated)

in flight

EU data residency · Paris region

in flight

Mammography density add-on

GA Jun 18

Q3 FY26

Cardiac CTA quant module

planned

FHIR R5 + SMART-on-FHIR launch app

planned

Federated learning · 4 EU partners

planned

Q4 FY26

Mobile reading workstation (iPadOS)

planned

Multi-modal report generation (LLM)

research

APAC data plane · Tokyo + Sydney

planned

Enterprise risk register

Risk	Impact	Likelihood	Owner	Mitigation
FDA timeline slip on Cardiac CTA	High	Medium	RA team	Pre-sub Q meeting scheduled Jun 12
GPU supply constraint H100 · 2026	High	Medium	Infra	Reserved L40S backstop · 18mo PO
EU AI Act high-risk classification	Medium	High	Legal/GRC	Conformity assessment in progress
Key competitor consolidation (M&A)	Medium	Medium	Strategy	Channel partnerships + UK lock-in